Extract from M&A Insights

The below story was originally featured in our daily M&A Insights Newsletter. Selected stories, including this one, are posted to our website with some weeks of delay.
Karo Pharma acquires a 10 product portfolio from Leo Pharma
March 1, 2018

Leo Pharma has divested a 10 product portfolio to Swedish-based Karo Pharma. It is fully aligned with Leo Pharma 2025 strategy to focus on new medical solutions and divest current. The deal value amounted to EUR 260 m.

ⓘ This story was originally featured in our daily M&A Insights newsletter.
Our insights have been covered by: